20-Year Study Finds Clozapine and Long-Acting Injectable Antipsychotics Most Effective at Preventing Re-Hospitalizations for Schizophrenia

September 21, 2018 · Posted in Current Treatments · Comment 

emergency room

Few studies have evaluated the comparative long-term effectiveness of antipsychotics in preventing relapse, but a 2017 study from Finland published in the journal Schizophrenia Bulletin by Heidi Taipale and colleagues did just that, and found that clozapine and long-acting injectable antipsychotic drugs were most effective at preventing psychiatric re-hospitalizations.

The Finnish health care registry was used to prospectively collect data on the treatment of every person who received inpatient care for schizophrenia between 1972 and 2014. The patients totaled 62,250 including 8,719 in their first episode of schizophrenia. Follow-up to evaluate antipsychotic use began at 1996 for those with ongoing treatment, and upon first discharge from the hospital for those patients in their first episode. The follow-up time ranged from 6.9 to 20 years with an average of 14.1 years. During the follow-up period, 59% of patients were readmitted to psychiatric inpatient care.

Among the drugs with the lowest rates of relapse, olanzapine long-acting injection, clozapine, and paliperidone long-acting injection were associated with the least risk of psychiatric re-hospitalization. Among patients in a first episode, taking flupentixol long-acting injection, olanzapine long-acting injection, or perphenazine long-acting injection had the lowest risk of psychiatric re-hospitalization. Clozapine and the long-acting injections also had the least risk of hospitalization for any cause.

Large Finnish Study Finds Lithium is Best at Preventing Re-Hospitalizations in Bipolar Disorder

June 13, 2018 · Posted in Current Treatments, Peer-Reviewed Published Data · Comment 

hospital

A 2018 article in the journal JAMA Psychiatry reports that lithium and long-acting antipsychotic injections were most effective at preventing re-hospitalizations among people with bipolar disorder.

The study by Markku Lähteenvuo and colleagues included 18,018 Finnish patients with bipolar disorder. A national database contained information on any hospitalizations that occurred among the patients and what medications were dispersed to patients.

Among the participants, 54% (9,721 patients) were re-hospitalized at least once over a study period of 16 years. Medications associated with the smallest risk of re-hospitalization for psychiatric reasons were long-acting injections of risperidone, gabapentin, long-acting injections of perphenazine, and lithium carbonate.
When the researchers looked at hospitalizations for any cause (not just psychiatric illness), lithium was associated with the least risk of re-hospitalization, while benzodiazepines had the greatest risk, both for psychiatric re-hospitalization and re-hospitalization for any cause.

Long-acting injectable medications were associated with less risk of re-hospitalization compared to the identical medications delivered orally.

Lähteenvuo and colleagues concluded, “Lithium…should remain as the first line of treatment for bipolar disorder, after decades of underprescription.” They suggest that long-acting injectable medications may be a good alternative to prevent relapse in patients for whom lithium is unsuitable.

Editor’s Note: In addition to lithium’s ability to prevent depressions and manias, it also increases the volume of the hippocampus and protects against a diagnosis of dementia in old age. Lithium decreases the risk for suicide and also increases the length of telomeres, bits on the ends of DNA strands that protect them as they replicate, which are important to the maintenance of both physical and psychiatric health. When lithium is used cautiously to maintain doses below a given patient’s side effects threshold, it is very well tolerated by most individuals.